Yousif Capital Management LLC Decreases Stake in Stryker Co. (NYSE:SYK)

Yousif Capital Management LLC decreased its holdings in shares of Stryker Co. (NYSE:SYK) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,858 shares of the medical technology company’s stock after selling 927 shares during the quarter. Yousif Capital Management LLC’s holdings in Stryker were worth $16,128,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Wedge Capital Management L L P NC grew its position in shares of Stryker by 16.2% in the third quarter. Wedge Capital Management L L P NC now owns 780 shares of the medical technology company’s stock valued at $213,000 after purchasing an additional 109 shares in the last quarter. Flagship Harbor Advisors LLC grew its holdings in Stryker by 2.5% in the 3rd quarter. Flagship Harbor Advisors LLC now owns 2,271 shares of the medical technology company’s stock valued at $621,000 after buying an additional 55 shares in the last quarter. DAVENPORT & Co LLC increased its stake in shares of Stryker by 5.1% in the 3rd quarter. DAVENPORT & Co LLC now owns 13,214 shares of the medical technology company’s stock worth $3,611,000 after acquiring an additional 642 shares during the last quarter. Founders Financial Securities LLC raised its holdings in shares of Stryker by 5.6% during the 3rd quarter. Founders Financial Securities LLC now owns 3,165 shares of the medical technology company’s stock worth $865,000 after acquiring an additional 167 shares during the period. Finally, Cedar Brook Financial Partners LLC boosted its position in shares of Stryker by 14.0% during the 3rd quarter. Cedar Brook Financial Partners LLC now owns 958 shares of the medical technology company’s stock valued at $262,000 after acquiring an additional 118 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In other news, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Allan C. Golston sold 3,273 shares of the firm’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the sale, the director now owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the sale, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The disclosure for this sale can be found here. Insiders have sold a total of 212,109 shares of company stock valued at $72,845,768 over the last 90 days. 5.50% of the stock is owned by corporate insiders.

Stryker Stock Up 0.6 %

SYK stock traded up $1.91 during midday trading on Wednesday, hitting $336.82. The company’s stock had a trading volume of 1,023,137 shares, compared to its average volume of 1,275,789. The firm has a 50-day simple moving average of $349.64 and a 200-day simple moving average of $314.08. The firm has a market capitalization of $128.15 billion, a P/E ratio of 40.85, a PEG ratio of 2.64 and a beta of 0.89. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $361.41.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The firm had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same period last year, the business posted $3.00 earnings per share. Stryker’s revenue was up 11.8% compared to the same quarter last year. As a group, equities analysts forecast that Stryker Co. will post 11.86 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a dividend of $0.80 per share. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.95%. Stryker’s payout ratio is 38.79%.

Wall Street Analyst Weigh In

A number of brokerages have commented on SYK. Truist Financial lifted their target price on shares of Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a research note on Wednesday, January 31st. Wells Fargo & Company upped their price objective on Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a report on Wednesday, January 31st. Citigroup lifted their target price on Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and increased their price target for the stock from $315.00 to $360.00 in a report on Wednesday, January 31st. Finally, TD Cowen boosted their price objective on shares of Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average price target of $340.67.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.